Serum MicroRNA Profiling in Patients with Glioblastoma: a Survival Analysis

Overview

Journal Mol Cancer

Publisher Biomed Central

Specialties Molecular Biology
Oncology

Date 2017 Mar 13

PMID 28284220

Citations 46

Authors

Hua Zhao

Jie Shen

Tiffany R Hodges

Renduo Song

Gregory N Fuller

Amy B Heimberger

Affiliations

Soon will be listed here.

Abstract

Because circulating microRNAs (miRNAs) have drawn a great deal of attention as promising novel cancer diagnostics and prognostic biomarkers, we sought to identify serum miRNAs significantly associated with outcome in glioblastoma patients. To do this, we performed global miRNA profiling in serum samples from 106 primary glioblastoma patients. The study subjects were randomly divided into two sets: set one (n = 40) and set two (n = 66). Using a Cox regression model, 3 serum miRNAs (miR-106a-5p, miR-182, and miR-145-5p) and 5 serum miRNAs (miR-222-3p, miR-182, miR-20a-5p, miR-106a-5p, and miR-145-5p) were identified significantly associated with 2-year patient overall survival and disease-free survival (P < 0.05) in both sets and the combined set. We then created the miRNA risk scores to assess the total impact of the significant serum miRNAs on survival. The high risk scores were associated with poor patient survival (overall survival: HR = 1.92, 95% CI: 1.19, 10.23, and disease-free survival: HR = 2.03, 95%CI: 1.24, 4.28), and were independent of other clinicopathological factors. Our results suggest that serum miRNAs could serve as prognostic predictors of glioblastoma.

Citing Articles

Analysis of Circulating Plasma MicroRNA Profile in Low-Grade and High-Grade Glioma - A Cross-Sectional Study.

Dwianingsih E, Hartanto R, Safitri S, Krisnugraha Y, Sianipar C, Basuki E F1000Res. 2025; 13():1361.

PMID: 39801574 PMC: 11725040. DOI: 10.12688/f1000research.153731.1.

Unlocking the Potential of Circulating miRNAs as Biomarkers in Glioblastoma.

Suvarnapathaki S, Serrano-Farias A, Dudley J, Bettegowda C, Rincon-Torroella J Life (Basel). 2024; 14(10).

PMID: 39459612 PMC: 11509808. DOI: 10.3390/life14101312.

Challenges and advances in glioblastoma targeted therapy: the promise of drug repurposing and biomarker exploration.

Bae W, Maraka S, Daher A Front Oncol. 2024; 14:1441460.

PMID: 39439947 PMC: 11493774. DOI: 10.3389/fonc.2024.1441460.

MicroRNAs as Biomarkers of Brain Tumor.

Jelski W, Mroczko B Cancer Manag Res. 2024; 16:1353-1361.

PMID: 39380890 PMC: 11460272. DOI: 10.2147/CMAR.S484158.

Serum CD133-Associated Proteins Identified by Machine Learning Are Connected to Neural Development, Cancer Pathways, and 12-Month Survival in Glioblastoma.

Joyce T, Tasci E, Jagasia S, Shephard J, Chappidi S, Zhuge Y Cancers (Basel). 2024; 16(15).

PMID: 39123468 PMC: 11311306. DOI: 10.3390/cancers16152740.

References

Kouri F, Hurley L, Daniel W, Day E, Hua Y, Hao L . miR-182 integrates apoptosis, growth, and differentiation programs in glioblastoma. Genes Dev. 2015; 29(7):732-45. PMC: 4387715. DOI: 10.1101/gad.257394.114. View

Shea A, Harish V, Afzal Z, Chijioke J, Kedir H, Dusmatova S . MicroRNAs in glioblastoma multiforme pathogenesis and therapeutics. Cancer Med. 2016; 5(8):1917-46. PMC: 4971921. DOI: 10.1002/cam4.775. View

Touat M, Duran-Pena A, Alentorn A, Lacroix L, Massard C, Idbaih A . Emerging circulating biomarkers in glioblastoma: promises and challenges. Expert Rev Mol Diagn. 2015; 15(10):1311-23. DOI: 10.1586/14737159.2015.1087315. View

Igaz I, Igaz P . Diagnostic Relevance of microRNAs in Other Body Fluids Including Urine, Feces, and Saliva. Exp Suppl. 2015; 106:245-252. DOI: 10.1007/978-3-0348-0955-9_11. View

Speranza M, Frattini V, Pisati F, Kapetis D, Porrati P, Eoli M . NEDD9, a novel target of miR-145, increases the invasiveness of glioblastoma. Oncotarget. 2012; 3(7):723-34. PMC: 3443255. DOI: 10.18632/oncotarget.547. View

Fernandez-Mercado M, Manterola L, Larrea E, Goicoechea I, Arestin M, Armesto M . The circulating transcriptome as a source of non-invasive cancer biomarkers: concepts and controversies of non-coding and coding RNA in body fluids. J Cell Mol Med. 2015; 19(10):2307-23. PMC: 4594673. DOI: 10.1111/jcmm.12625. View

Malzkorn B, Wolter M, Liesenberg F, Grzendowski M, Stuhler K, Meyer H . Identification and functional characterization of microRNAs involved in the malignant progression of gliomas. Brain Pathol. 2009; 20(3):539-50. PMC: 8094849. DOI: 10.1111/j.1750-3639.2009.00328.x. View

Xu S, Wang J, Ding N, Hu W, Zhang X, Wang B . Exosome-mediated microRNA transfer plays a role in radiation-induced bystander effect. RNA Biol. 2015; 12(12):1355-63. PMC: 4829325. DOI: 10.1080/15476286.2015.1100795. View

van der Vos K, Abels E, Zhang X, Lai C, Carrizosa E, Oakley D . Directly visualized glioblastoma-derived extracellular vesicles transfer RNA to microglia/macrophages in the brain. Neuro Oncol. 2015; 18(1):58-69. PMC: 4677420. DOI: 10.1093/neuonc/nov244. View

10.

Zhi F, Shao N, Wang R, Deng D, Xue L, Wang Q . Identification of 9 serum microRNAs as potential noninvasive biomarkers of human astrocytoma. Neuro Oncol. 2014; 17(3):383-91. PMC: 4483096. DOI: 10.1093/neuonc/nou169. View

11.

Wei J, Wang F, Kong L, Xu S, Doucette T, Ferguson S . miR-124 inhibits STAT3 signaling to enhance T cell-mediated immune clearance of glioma. Cancer Res. 2013; 73(13):3913-26. PMC: 3780786. DOI: 10.1158/0008-5472.CAN-12-4318. View

12.

Anindo M, Yaqinuddin A . Insights into the potential use of microRNAs as biomarker in cancer. Int J Surg. 2012; 10(9):443-9. DOI: 10.1016/j.ijsu.2012.08.006. View

13.

Diaz Jr L, Bardelli A . Liquid biopsies: genotyping circulating tumor DNA. J Clin Oncol. 2014; 32(6):579-86. PMC: 4820760. DOI: 10.1200/JCO.2012.45.2011. View

14.

Kouri F, Ritner C, Stegh A . miRNA-182 and the regulation of the glioblastoma phenotype - toward miRNA-based precision therapeutics. Cell Cycle. 2015; 14(24):3794-800. PMC: 4825743. DOI: 10.1080/15384101.2015.1093711. View

15.

Healy N, Heneghan H, Miller N, Osborne C, Schiff R, Kerin M . Systemic mirnas as potential biomarkers for malignancy. Int J Cancer. 2012; 131(10):2215-22. DOI: 10.1002/ijc.27642. View

16.

Ilhan-Mutlu A, Wagner L, Wohrer A, Furtner J, Widhalm G, Marosi C . Plasma MicroRNA-21 concentration may be a useful biomarker in glioblastoma patients. Cancer Invest. 2012; 30(8):615-21. DOI: 10.3109/07357907.2012.708071. View

17.

Yue X, Lan F, Hu M, Pan Q, Wang Q, Wang J . Downregulation of serum microRNA-205 as a potential diagnostic and prognostic biomarker for human glioma. J Neurosurg. 2015; 124(1):122-8. DOI: 10.3171/2015.1.JNS141577. View

18.

Karsy M, Arslan E, Moy F . Current Progress on Understanding MicroRNAs in Glioblastoma Multiforme. Genes Cancer. 2012; 3(1):3-15. PMC: 3415667. DOI: 10.1177/1947601912448068. View

19.

Wei J, Nduom E, Kong L, Hashimoto Y, Xu S, Gabrusiewicz K . MiR-138 exerts anti-glioma efficacy by targeting immune checkpoints. Neuro Oncol. 2015; 18(5):639-48. PMC: 4827047. DOI: 10.1093/neuonc/nov292. View

20.

Louis D, Ohgaki H, Wiestler O, Cavenee W, Burger P, Jouvet A . The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol. 2007; 114(2):97-109. PMC: 1929165. DOI: 10.1007/s00401-007-0243-4. View